Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.61 |
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | CPA1 | P15085 | 4/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.56 |
| ▸ | GNPAT | O15228 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8068319 | 1.00 | MME (0.61) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL4432590 | 0.94 | CTSC (0.60) | MMEACEITGB3ITGA2BCTSC | |
| SCHEMBL232698 | 0.94 | CTSC (0.60) | MMEACEITGB3ITGA2BCTSC | |
| SCHEMBL232699 | 0.94 | CTSC (0.60) | MMEACEITGB3ITGA2BCTSC | |
| SCHEMBL31607204 | 0.93 | MME (0.55) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL29350849 | 0.93 | MME (0.63) | MMEACE | |
| SCHEMBL29603463 | 0.93 | MME (0.63) | MMEACE | |
| SCHEMBL13588078 | 0.93 | MME (0.63) | MMEACE | |
| SCHEMBL29602654 | 0.93 | MME (0.63) | MMEACE | |
| SCHEMBL30900762 | 0.93 | MME (0.59) | MMEACECPA1ACE2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| US-12350337-B2 | Polymeric drug delivery conjugates and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-07-08 | — | — | US | claimed |
| WO-2024222960-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | 上海弼领生物技术有限公司 | 2024-10-31 | — | — | WO | claimed |
| EP-4431116-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2024-09-18 | — | — | EP | claimed |
| CN-118284435-A | Drug conjugate based on epsilon-poly-L-lysine, intermediate and application thereof | 上海弼领生物技术有限公司 | 2024-07-02 | — | — | CN | claimed |
| US-11801307-B2 | Antibody-polymer-drug conjugates | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-10-31 | — | — | US | claimed |
| WO-2023078464-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海弼领生物技术有限公司 | 2023-05-11 | — | — | WO | claimed |
| EP-4045087-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2022-08-24 | — | — | EP | claimed |
| US-20220249682-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2022-08-11 | — | — | US | claimed |
| EP-4746916-A2 | CLEAVABLE POLYMER-DRUG CONJUGATES FOR ALZHEIMER'S DISEASE | University of Utah Research Foundation (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | disclosed |
| US-12350337-B2 | Polymeric drug delivery conjugates and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-07-08 | — | — | US | disclosed |
| EP-0425104-A1 | Column packing material | SHISEIDO COMPANY LIMITED (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4941974-A | Method of making liquid chromatography dual zone packing materials | DOW CORNING CORPORATION (US) | 1990-07-17 | — | — | US | disclosed |
| US-4855054-A | BIOLOGICAL ANALYSIS USING A POROUS SUPPORT WITH PERFLUORO-ALKYLSILYL GROUPS AS EXTERNAL LIPOPHOBIC PHASE TO REJECT PROTEINS; INTERNAL LIPOPHILIC PHASE ABSORBS DRUGS AND SMALL MOLECULES | DOW CORNING CORPORATION (US) | 1989-08-08 | — | — | US | disclosed |
| EP-0295809-A2 | Liquid chromatography dual zone packing materials and method for making and using same | DOW CORNING CORPORATION (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4778600-A | LIPOPHOBIC FLUOROCARBON PHASE REJECTS PROTEINS; LIPOPHILIC PARTITIONING PHASE RETAINS SMALL MOLECULES; BLOOD ANALYSIS | DOW CORNING CORPORATION (US) | 1988-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | MME 824/4885ACE 1190/4885CPA1 245/4885 |
| US-12350337-B2 | Polymeric drug delivery conjugates and methods of making and using thereof | PDCD1LG2, CD274, PDCD1 | MME 1034/4885ACE 1554/4885CPA1 1598/4885 |
| US-11801307-B2 | Antibody-polymer-drug conjugates | FCGR1A, FCGR2A, CD79B | MME 880/4885ACE 2799/4885CPA1 2356/4885 |
| US-20220249682-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | PDCD1LG2, CD274, PDCD1 | MME 1034/4885ACE 1554/4885CPA1 1598/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | MME 946/4885ACE 1805/4885CPA1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.